SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 from Investment in CytRx Corporation to Contact Brower Piven Before the May 13, 2014 Lead Plaintiff Deadline
Business Wire - Tue Apr 15, 9:00PM CDT
Brower Piven, A Professional Corporation announces that a class action lawsuit has been commenced in the United States District Court for the Central District of California on behalf of purchasers of CytRx Corporation ("CytRx" or the "Company"
Wolf Haldenstein Adler Freeman & Herz LLP Reminds Investors of the May 13, 2014 Deadline to File for Lead Plaintiff in the Securities Fraud Class Action Against CytRx Corporation -- CYTR
GlobeNewswire - Tue Apr 15, 3:15PM CDT
Wolf Haldenstein Adler Freeman & Herz LLP reminds investors of the May 13, 2014 deadline to file for lead plaintiff in the securities fraud class action against CytRx Corporation (Nasdaq:CYTR) ("CytRx" or "the Company"
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against CYTRX CORPORATION and Its Board of Directors and a Lead Plaintiff Deadline of May 13, 2014 -- CYTR
PR Newswire - Fri Apr 11, 1:42PM CDT
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Central District of California on behalf of investors who purchased CytRx Corporation ("CytRx" or the "Company"
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Lead Plaintiff Deadline in the Class Action Lawsuit Against CytRx Corporation
Business Wire - Thu Apr 10, 9:32AM CDT
Law Offices of Howard G. Smith reminds investors that all purchasers of the securities of CytRx Corporation ("CytRx" or the "Company"
CytRx Announces Research and Development Day and Webcast
Business Wire - Thu Apr 10, 6:01AM CDT
CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that the Company will host a Research and Development Day on Friday, May 2, from 8:30 - 11:30 am EDT at the Harvard Club in New York City.
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against CytRx Corporation and Certain Officers -- CYTR
GlobeNewswire - Wed Apr 09, 4:10PM CDT
Pomerantz LLP announces the filing of a class action lawsuit against CytRx Corporation ("CytRx" or the "Company"
Hagens Berman Reminds CytRx Investors of May 13, 2014 Lead Plaintiff Deadline and Inclusion of Those Who Purchased Stock from Feb. 5, 2014 Offering
Business Wire - Wed Apr 09, 12:24PM CDT
Hagens Berman Sobol Shapiro LLP reminds investors of the May 13, 2014 deadline to file for lead plaintiff in the securities fraud class action against CytRx Corporation (NASDAQ: CYTR) ("CytRx" or "the Company"
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in CytRx Corporation to Contact Brower Piven Before the May 13, 2014 Lead Plaintiff Deadline -- CYTR
GlobeNewswire - Tue Apr 08, 3:05PM CDT
Brower Piven, A Professional Corporation announces that a class action lawsuit has been commenced in the United States District Court for the Central District of California on behalf of purchasers of CytRx Corporation ("CytRx" or the "Company"
Technical Update on Active Stocks -- Research on CytRx, FireEye, Yandex, and Hewlett-Packard
PR Newswire - Fri Apr 04, 11:40AM CDT
The trading session on Thursday, April 3, 2014 ended on a lower note as the Dow Jones Industrial Average finished flat at 16,572.55 and the NASDAQ Composite closed at 4,237.74, down 0.91%. The S&P 500 finished the session 0.11% lower at 1,888.77. The session saw a positive impact from Energy, Utilities and Telecommunication Services sectors along with a drag from Consumer Discretionary, Information Technology and Health Care sectors. Investor-Edge looks at some of the equities which attracted the most attention and traded the most shares during the session. These include CytRx Corp. (NASDAQ: CYTR), FireEye Inc. (NASDAQ: FEYE), Yandex N.V. (NASDAQ: YNDX) and Hewlett-Packard Co. (NYSE: HPQ). Free technical research on CYTR, FEYE, YNDX and HPQ can be downloaded upon signing up at:
The Shuman Law Firm Investigates CytRx Corporation
Business Wire - Thu Apr 03, 7:00PM CDT
The Shuman Law Firm announces that it is investigating potential claims against certain officers and directors of CytRx Corp. ("CytRx" or the "Company"
Why CytRx (CYTR) Stock Is Surging Today
at The Street - Thu Apr 03, 11:24AM CDT
The biopharmaceutical R&D firm announced that positive preclinical results from an in vivo study of aldoxorubicin in an animal model of glioblastoma will be presented at the American Association for Cancer Research Annual Meeting
Stock to Watch: CytRx Up 13.6% (CYTR)
Comtex SmarTrend(R) - Thu Apr 03, 10:11AM CDT
CytRx (NASDAQ:CYTR) is one of today's best performing low-priced stocks, up 13.6% to $4.33 on 2.7x average daily volume. Thus far today, CytRx has traded 7.2 million shares, vs. average volume of 2.7 million shares per day. The stock has outperformed the Dow (13.6% to the Dow's -0.1%) and outperformed the S&P 500 (13.6% to the S&P's -0.1%) during today's trading.
INVESTOR ALERT: Class Action Lawsuit against CytRx Corporation Announced by Law Offices of Howard G. Smith
Business Wire - Thu Apr 03, 9:32AM CDT
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed in the United States District Court for the Central District of California on behalf of all purchasers of the securities of CytRx Corporation ("CytRx" or the "Company"
CytRx to Present Updated Aldoxorubicin Preclinical Glioblastoma Study Results at the 2014 AACR Annual Meeting
Business Wire - Thu Apr 03, 6:00AM CDT
CytRx Corporation (Nasdaq:CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that positive preclinical results from an in vivo study of aldoxorubicin in an animal model of glioblastoma will be presented at the American Association for Cancer Research Annual Meeting being held April 5-9, 2014 in San Diego, CA.
Speculative Biotech Stock Offers Opportunity Amid Controversy
at The Street - Tue Apr 01, 2:10PM CDT
CytRx has dug itself a deep hole recently, but the technical picture for the stock might be looking up.
CORRECTING and REPLACING Hagens Berman Reminds CytRx Investors of May 13, 2014 Lead Plaintiff Deadline and Continued Securities Fraud Investigation
Business Wire - Mon Mar 31, 1:49PM CDT
Third graph, last sentence has been omitted.
Hagens Berman Reminds CytRx Investors of May 13, 2014 Lead Plaintiff Deadline and Continued Securities Fraud Investigation
Business Wire - Mon Mar 31, 12:19PM CDT
Hagens Berman Sobol Shapiro LLP, reminds investors of the May 13, 2014 deadline to file for lead plaintiff in the securities fraud class action against CytRx Corporation (NASDAQ: CYTR) ("CytRx"
CytRx Receives Orphan Medicinal Product Designation from the European Commission for Aldoxorubicin in Soft Tissue Sarcoma
Business Wire - Mon Mar 31, 6:00AM CDT
CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that aldoxorubicin has received orphan medicinal product designation from the European Commission for the treatment of advanced soft tissue sarcomas. The designation is to encourage the development of drugs which may provide significant benefit to patients suffering from rare diseases.
Cohen Milstein Sellers & Toll PLLC Announces the Investigation of CytRx Corporation
Business Wire - Fri Mar 28, 8:55AM CDT
Cohen Milstein Sellers & Toll PLLC is conducting an investigation to determine whether CytRx Corporation ("CYTR" or the "Company"